Cytokinetics Highlights Phase 3 Aficamten Data at ESC
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 Cytokinetics, Incorporated announced additional clinical data for aficamten from the ACACIA-HCM and...
Cytokinetics
Advertisement
CND Life Sciences’ Syn-One® Biomarker Services Advance Parkinson’s Research in Phase 2 Clinical Trial
PHOENIX, AZ – November 11, 2025 — CND Life Sciences, a pioneering neurodiagnostic company, announced that its Syn-One® Biomarker...
Cytokinetics Presents New MAPLE-HCM Data at AHA 2025, Strengthening Pipeline in Rare Cardiomyopathy Therapy
San Francisco, November 10, 2025 — Cytokinetics, Inc., a biopharmaceutical company focused on developing muscle biology–driven therapies, announced the...
Advertisement
